Q-omics provides the consensus-scored IGKV1D-32 profile across patient tissues and cancer cell-line models. IGKV1D-32 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, IGKV1D-32 is differentially expressed in 4, with the highest sampling consensus in LUAD. Additionally, IGKV1D-32 RNA expression shows 6,141 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, LUAD, and STAD as cancer lineages where IGKV1D-32 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGKV1D-32 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGKV1D-32 survival associations across molecular data types. IGKV1D-32 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGKV1D-32 RNA expression–survival associations across cancer types. High IGKV1D-32 expression shows unfavorable associations in UVM, KICH, MESO, GBM and PAAD, but favorable associations in HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for IGKV1D-32 RNA expression.
This table summarizes IGKV1D-32 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for IGKV1D-32. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGKV1D-32 shows lower tumor expression in COAD, BRCA and READ and higher tumor expression in LUAD. The LUAD box plot shows higher IGKV1D-32 RNA expression in tumor versus normal tissue (log2 FC = +0.251, t-test p < 0.001).
This table shows molecular features associated with IGKV1D-32 in patient tissues and cancer cell lines. In patient samples, IGKV1D-32 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
